96% of patients with HIV in Mexico receive treatment: IMSS

The Mexican Social Security Institute (IMSS) reported that the 96% of beneficiaries living with HIV in the country, receive antiretroviral treatment.

Thus, the IMSS exceeds the established goal by the Joint United Nations Program on HIV/AIDS (UNAIDS) which is 95%.

Of July 2021 to June 2022 IMSS provided medical care to 82,716 people living with HIV.

This December 1st, on the occasion of the World AIDS Day, The general director of the IMSS, Zoé Robledo, said that the Institute makes many efforts on a daily basis focused on the prevention, detection, treatment and monitoring of people living with HIV, such as optimization of antiretroviral treatment.

Among these, the following stand out: optimization of antiretroviral treatments, participation in mass detection campaignscombined prevention through detection in pregnant women and in the population at risk of acquiring this disease.

Likewise, he stated that the implementation of the Universal pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP)or tools such as the virtual Chatbot service, allow a better knowledge of the population that lives with this disease.

“They are implementing education protocols, awareness so that discrimination does not occur in the IMSS and there is always dignified and equal treatment,” said Robledo.

Dr. Sandra Treviño Pérez, head of the Special Programs Area of ​​the Clinical Excellence Division of the Health Innovation Coordination, reported that currently it has been achieved that 91% of patients have undetectable viral load.

It does not mean that they do not have the infection.but the levels are so low that the standard viral load tests that determine the amount of virus in the body practically do not detect it, ”he explained.

See also  Fortnite will reportedly add Lebron James skin

He indicated that from the triple optimization strategy implemented at the sectoral level, 96% of patients with antiretroviral treatment in the IMSS take one of the two latest generation therapies based on inhibitors of integrase, mainly with bictegravir and to a lesser extent with dolutegravir.


Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *